RhumbLine Advisers’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Shares
Change %
Capital Flow Portfolio Weight Portfolio Position
2024
Q1
Sell
-61,220
Closed -$3.6M 4302
2023
Q4
$3.6M Buy
61,220
+9,349
+18% +$549K ﹤0.01% 1601
2023
Q3
$2.26M Buy
51,871
+424
+0.8% +$18.5K ﹤0.01% 1795
2023
Q2
$1.86M Buy
51,447
+3,010
+6% +$109K ﹤0.01% 1949
2023
Q1
$1.8M Sell
48,437
-817
-2% -$30.4K ﹤0.01% 1857
2022
Q4
$2.23M Buy
49,254
+3,091
+7% +$140K ﹤0.01% 1721
2022
Q3
$3.22M Buy
46,163
+7,021
+18% +$490K ﹤0.01% 1497
2022
Q2
$2.63M Buy
39,142
+3,608
+10% +$242K ﹤0.01% 1623
2022
Q1
$2.92M Sell
35,534
-2,921
-8% -$240K ﹤0.01% 1610
2021
Q4
$5.64M Buy
38,455
+2,178
+6% +$319K 0.01% 1287
2021
Q3
$6.42M Sell
36,277
-932
-3% -$165K 0.01% 1203
2021
Q2
$6.01M Sell
37,209
-11,934
-24% -$1.93M 0.01% 1328
2021
Q1
$8.42M Sell
49,143
-4,650
-9% -$797K 0.01% 1102
2020
Q4
$11.8M Buy
53,793
+6,715
+14% +$1.47M 0.02% 822
2020
Q3
$7.82M Sell
47,078
-9,597
-17% -$1.59M 0.01% 893
2020
Q2
$6.47M Buy
56,675
+15,398
+37% +$1.76M 0.01% 1044
2020
Q1
$3.17M Buy
41,277
+3,307
+9% +$254K 0.01% 1290
2019
Q4
$4.89M Buy
37,970
+2,465
+7% +$318K 0.01% 1265
2019
Q3
$2.77M Buy
35,505
+2,015
+6% +$157K 0.01% 1553
2019
Q2
$3.45M Buy
33,490
+6,126
+22% +$631K 0.01% 1405
2019
Q1
$2.01M Buy
27,364
+1,123
+4% +$82.3K ﹤0.01% 1714
2018
Q4
$1.11M Buy
26,241
+9,385
+56% +$398K ﹤0.01% 1953
2018
Q3
$794K Buy
16,856
+86
+0.5% +$4.05K ﹤0.01% 2098
2018
Q2
$827K Buy
+16,770
New +$827K ﹤0.01% 2099
2017
Q2
Sell
-16,954
Closed -$88K 2969
2017
Q1
$88K Buy
16,954
+5,325
+46% +$27.6K ﹤0.01% 2787
2016
Q4
$55K Sell
11,629
-1,458
-11% -$6.9K ﹤0.01% 2824
2016
Q3
$87K Buy
13,087
+100
+0.8% +$665 ﹤0.01% 2822
2016
Q2
$71K Buy
12,987
+1,890
+17% +$10.3K ﹤0.01% 2947
2016
Q1
$237K Buy
11,097
+130
+1% +$2.78K ﹤0.01% 2650
2015
Q4
$347K Buy
10,967
+2,330
+27% +$73.7K ﹤0.01% 2481
2015
Q3
$297K Buy
8,637
+392
+5% +$13.5K ﹤0.01% 2544
2015
Q2
$259K Buy
+8,245
New +$259K ﹤0.01% 2752